John T. Spitznagel

Biography

John Spitznagel is CEO of NovaSom, a leading provider of home sleep testing for obstructive sleep apnea. Prior to joining NovaSom, he built 4 high growth healthcare companies as CEO (3 as co-founder) with exit valuations from $300 million to over $1 billion. Before NovaSom, John served as Chairman and CEO of Oceana Therapeutics, Inc., a medical device company he co-founded focused on pediatric urology and colon and rectal surgery (acquired by Salix for $300 million). Prior to Oceana, John served as Chairman and CEO of Esprit Pharma, Inc., a specialty pharmaceutical company he co-founded focused on the genito-urinary market (acquired by Allergan for $360 million). Prior to Esprit, John was Chairman & CEO of ESP Pharma, a company he co-founded to pursue the acquisition, development, and marketing of acute-care pharmaceuticals (acquired by Protein Design Labs for $500 million). Previous leadership positions included serving as President & CEO of Roberts Pharmaceutical before its successful merger into Shire, and as President of the Reed and Carnrick Division of Block Drug. John began his career at Warner-Lambert in sales and marketing and held senior commercial roles at Hoffmann-La Roche, American Home Products, and Wyeth. John received a BA from Rider University and an MBA from Fairleigh Dickinson University.

Research Interest

 Cancer